Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Gilead Sciences Inc (GILD) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 18,000 employees
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Total Value
-$18,264,675.22
Total Shares
1,719,387
Average Trade Value
-$280,995.00
Most Active Insider
Dickinson Andrew D
Total Activity: $41,668,175
Largest Single Transaction
$11,867,119
by Dickinson Andrew D on Nov 29, 2024
30-Day Activity
31 Transactions
Volume: 1,745,055 shares
Value: $11,492,175
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
10% Owner
|
Dec 18, 2024 | 1,759,978 | $1,830,377 | 9,105,451 (+19.3%) | Purchase | |
Chief Financial Officer
Officer
|
Dec 16, 2024 | 8,500 | $781,660 | 132,373 (-6.4%) | Sale | |
Svp, Controllership
Officer
|
Dec 13, 2024 | 157 | $10,000 | 37,533 (+0.4%) | Exercise/Conversion | |
Svp, Controllership
Officer
|
Dec 13, 2024 | 157 | $14,421 | 37,078 (-0.4%) | Payment of Exercise Price | |
Chief Financial Officer
Officer
|
Dec 10, 2024 | 3,640 | $0 | 142,559 (+2.6%) | Exercise/Conversion | |
Chairman CEO
Director, Officer
|
Dec 10, 2024 | 10,295 | $0 | 506,290 (+2.0%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Dec 10, 2024 | 306 | $28,256 | 21,312 (-1.4%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Dec 10, 2024 | 901 | $0 | 37,486 (+2.4%) | Exercise/Conversion | |
Chief Commercial Officer
Officer
|
Dec 10, 2024 | 1,739 | $160,579 | 75,140 (-2.3%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Dec 10, 2024 | 408 | $37,675 | 37,078 (-1.1%) | Payment of Exercise Price | |
Evp, Corporate Affairs Gc
Officer
|
Dec 10, 2024 | 639 | $0 | 21,618 (+3.0%) | Exercise/Conversion | |
Chairman CEO
Director, Officer
|
Dec 10, 2024 | 4,762 | $439,723 | 501,528 (-0.9%) | Payment of Exercise Price | |
Chief Commercial Officer
Officer
|
Dec 10, 2024 | 3,752 | $0 | 76,879 (+4.9%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Dec 10, 2024 | 3,820 | $0 | 84,621 (+4.5%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Dec 10, 2024 | 1,686 | $155,685 | 140,873 (-1.2%) | Payment of Exercise Price | |
Chief Medical Officer
Officer
|
Dec 10, 2024 | 1,771 | $163,534 | 82,850 (-2.1%) | Payment of Exercise Price | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 26,170 | $1,515,766 | 183,719 (+14.2%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 65,960 | $4,795,292 | 387,564 (+17.0%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 127,930 | $11,867,119 | 138,919 (-92.1%) | Sale | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 33,660 | $2,314,125 | 217,379 (+15.5%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 120,715 | $11,198,151 | 266,849 (-45.2%) | Sale | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 18,630 | $1,374,335 | 157,549 (+11.8%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 60,885 | $4,378,240 | 278,264 (+21.9%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 43,340 | $3,150,818 | 321,604 (+13.5%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 10,399 | $956,708 | 80,801 (-12.9%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 5,200 | $477,381 | 94,399 (-5.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 88,119 | $5,761,220 | 245,012 (+36.0%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 3,199 | $293,679 | 91,200 (-3.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 57,294 | $3,318,468 | 156,893 (+36.5%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 88,119 | $8,106,948 | 99,599 (-88.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 57,294 | $5,259,297 | 187,718 (-30.5%) | Sale | |
Director
|
Nov 26, 2024 | 4,121 | $252,823 | 15,708 (+26.2%) | Exercise/Conversion | |
Director
|
Nov 26, 2024 | 5,879 | $359,618 | 11,587 (+50.7%) | Exercise/Conversion | |
Director
|
Nov 26, 2024 | 6,788 | $620,356 | 8,920 (-76.1%) | Sale | |
Chief Medical Officer
Officer
|
Nov 6, 2024 | 25,000 | $1,448,000 | 125,189 (+20.0%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Nov 6, 2024 | 5,000 | $457,500 | 99,599 (-5.0%) | Sale | |
Chief Commercial Officer
Officer
|
Nov 6, 2024 | 5,000 | $456,400 | 73,127 (-6.8%) | Sale | |
Chief Medical Officer
Officer
|
Nov 6, 2024 | 20,590 | $1,883,985 | 104,599 (-19.7%) | Sale | |
Evp, Corporate Affairs Gc
Officer
|
Oct 25, 2024 | 242 | $21,538 | 20,979 (-1.2%) | Payment of Exercise Price | |
Evp, Corporate Affairs Gc
Officer
|
Oct 25, 2024 | 514 | $0 | 21,221 (+2.4%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Oct 1, 2024 | 2,000 | $167,660 | 100,189 (-2.0%) | Sale | |
Chief Commercial Officer
Officer
|
Sep 12, 2024 | 15,925 | $1,341,363 | 91,559 (-17.4%) | Sale | |
Chief Commercial Officer
Officer
|
Sep 12, 2024 | 13,432 | $1,118,214 | 78,127 (-17.2%) | Sale | |
Chief Medical Officer
Officer
|
Sep 12, 2024 | 25,000 | $1,448,000 | 123,435 (+20.3%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Sep 12, 2024 | 21,246 | $1,795,287 | 102,189 (-20.8%) | Sale | |
Chief Commercial Officer
Officer
|
Sep 10, 2024 | 1,734 | $141,217 | 107,484 (-1.6%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Sep 10, 2024 | 901 | $0 | 36,877 (+2.4%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Sep 10, 2024 | 307 | $25,002 | 20,707 (-1.5%) | Payment of Exercise Price | |
Chief Medical Officer
Officer
|
Sep 10, 2024 | 3,821 | $0 | 100,201 (+3.8%) | Exercise/Conversion | |
Svp, Controllership
Officer
|
Sep 10, 2024 | 292 | $23,780 | 36,585 (-0.8%) | Payment of Exercise Price | |
Chairman CEO
Director, Officer
|
Sep 10, 2024 | 4,749 | $386,759 | 495,995 (-1.0%) | Payment of Exercise Price | |
Chief Financial Officer
Officer
|
Sep 10, 2024 | 3,641 | $0 | 140,601 (+2.6%) | Exercise/Conversion | |
Chief Commercial Officer
Officer
|
Sep 10, 2024 | 3,752 | $0 | 109,218 (+3.4%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Sep 10, 2024 | 1,682 | $136,982 | 138,919 (-1.2%) | Payment of Exercise Price | |
Evp, Corporate Affairs Gc
Officer
|
Sep 10, 2024 | 639 | $0 | 21,014 (+3.0%) | Exercise/Conversion | |
Chairman CEO
Director, Officer
|
Sep 10, 2024 | 10,295 | $10,000 | 500,744 (+2.1%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Sep 10, 2024 | 1,766 | $143,823 | 98,435 (-1.8%) | Payment of Exercise Price | |
Chief Commercial Officer
Officer
|
Aug 28, 2024 | 9,513 | $742,299 | 105,466 (-9.0%) | Sale | |
Chief Commercial Officer
Officer
|
Aug 13, 2024 | 5,490 | $406,150 | 114,979 (-4.8%) | Sale | |
Svp, Controllership
Officer
|
Aug 10, 2024 | 980 | $72,187 | 35,976 (-2.7%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Aug 10, 2024 | 3,678 | $10,000 | 36,956 (+10.0%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Jul 25, 2024 | 514 | $0 | 12,145 (+4.2%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Jul 25, 2024 | 2,917 | $223,180 | 11,631 (-25.1%) | Payment of Exercise Price | |
Evp, Corporate Affairs Gc
Officer
|
Jul 25, 2024 | 8,230 | $0 | 20,375 (+40.4%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Jul 1, 2024 | 2,000 | $137,260 | 96,380 (-2.1%) | Sale |